Spain is suspending the use of the coronavirus vaccine from the British-Swedish company AstraZeneca for at least 15 days, Radio Cadena Ser reported March 15.
The decision was taken “as a precautionary measure,” said Spanish Health Minister Carolina Darias.
She has called an emergency meeting of the inter-territorial health council to discuss the suspension of the vaccine amid reports of clotting disorders.
Authorities in the autonomous communities of Andalusia, Castilla y Leon and Asturias suspended its use as early as March 12 after reports of an increased risk of thrombosis after vaccination with the drug from AstraZeneca.
In this case, the Spanish Agency for Medicines and Healthcare Products (AEMPS) assured that no cases of thromboembolism after vaccination have been recorded in the kingdom and there is no reason to stop vaccination with AstraZeneca.
On March 15, it became known that a patient died in Denmark after being vaccinated with AstraZeneca. The country’s medical agency reported similar symptoms to the clinical picture in several reports in European databases. The woman had a low platelet count, blood clots in small and large vessels, and bleeding.
On the same day, Steinar Madsen, director of the Norwegian Medicines Agency, reported that a medic who had previously been hospitalized due to worsening conditions after vaccination with the drug in question had died in Norway.
Against this background, the use of the AstraZeneca vaccine was suspended in Germany, Italy and France, Denmark, Ireland, Iceland, Romania, Bulgaria and the Netherlands.
The World Health Organization (WHO) announced the start of a study of evidence of blood clots in those vaccinated with the AstraZeneca vaccine.